An observational cohort study was conducted to compare the performance of the RIFLE (risk, injury, failure, loss and end-stage kidney disease), AKIN (acute kidney injury network) and conventional graded criteria to identify acute kidney injury (AKI) following SCT and to predict long-term mortality in 141 myeloablative allogeneic SCT (m-allo), 60 non-myeloablative allogeneic SCT (nm-allo) and 48 autologous SCT (auto) cases. The AKIN criteria had less ability to identify patients as having the lowest category, stage 1 (analogous to RIFLE risk): 33% (37%) in m-allo, 23% (32%) in nm-allo and 8.3% (16.7%) in auto. Cox regression showed that categories higher than the intermediate stage were independent predictors of mortality in all three definitions. The areas under receiver operating characteristic curves showed that both definition systems had similar and significant ability to predict mortality (0.643-0.649 in m-allo and 0.734-0.766 in nmallo, respectively). These abilities of the conventional graded criteria were comparable with those of the RIFLE criteria. The RIFLE criteria have greater sensitivity than the AKIN criteria to identify patients with AKI and therefore are more favorable as a uniform definition system for post-SCT AKI. However, the RIFLE criteria do not improve on the clinical relevance of the conventional graded criteria.
Introduction
Acute kidney injury (AKI) is a common early complication after hematopoietic SCT. 1, 2 Recent reports have also shown that AKI associated with SCT results in poor long-term survival of affected patients. 3, 4 At present, there are three major SCT modalities that include autologous SCT (auto), myeloablative allogeneic SCT (m-allo) and non-myeloablative allogeneic SCT (nm-allo), with selection depending on stem cell sources and preconditioning procedures. AKI is a common complication of all these SCT modalities, although the incidence, severity and impact on mortality differ between the three modalities. Schrier et al. 5 showed the frequency of AKI increased significantly from auto (21%) to nm-allo (40%) to m-allo (69%), and that the increased incidence of AKI correlated with a parallel increase in mortality 6-12 months after SCT from 7 to 34 to 58%, respectively. However, the clinical validity of such epidemiological data needs to be re-examined from the viewpoint of the contemporary paradigm for AKI, as these earlier studies were conducted according to conventional, but likely arbitrary definition systems, used at that time.
The lack of consensus concerning the quantitative definition of AKI has hindered clinical research as it confounds comparisons between studies. Thus, the Acute Dialysis Quality Initiative (ADQI) group has proposed a new graded definition for AKI, called the RIFLE criteria (risk, injury, failure, loss of kidney function, end-stage kidney disease), to establish a uniform standard for diagnosing and classifying AKI. 6 More recently, the acute kidney injury network (AKIN) proposed new diagnostic criteria and a three-staging system for AKI modified from RIFLE, with the aim of increasing the sensitivity of the classifications. 7 These criteria have now been evaluated in a number of clinical studies of critically ill patients with AKI and have been shown to be able to identify and classify the severity of AKI and monitor progression of the disorder, in addition to being a predictive index of in-hospital mortality. [8] [9] [10] It is possible that these new AKI criteria may have great utility in standardizing the definitions for establishing inclusion criteria and outcomes for post-SCT AKI. However, it is unknown currently whether discernible advantages exist between RIFLE, AKIN and the conventional graded criteria for classifying post-HCT AKI introduced by Parikh et al. 5, 11, 12 The objectives of this study were (1) to determine the current incidence of post-SCT AKI according to the two new definition systems, and (2) to compare the performance of the RIFLE, AKIN and the conventional graded criteria for identifying AKI and predicting long-term all-cause mortality associated with post-SCT AKI in the three major SCT modalities
Patients and methods
The subjects were 249 Japanese patients (mean age, 41.7±12.5 years; 157 males) who received SCT between August 2004 and December 2007 in the Department of Hematology at Tokyo Metropolitan Cancer Center Komagome Hospital. This cohort comprised 141 myeloablative allogeneic SCTs (m-allo), 60 non-myeloablative allogeneic SCTs (nm-allo) and 48 myeloablative autologous SCTs (auto). Candidates for allogeneic myeloablative SCT were screened for the presence of pre-existing comorbidities and deemed suitable for the procedure on the basis of normal kidney morphology and a 24 h timed urine creatinine (Cr) clearance X80 ml/min and albuminuria p300 mg/gCr. Patients older than X50 years or with other comorbidities such as hypertension, diabetes and hepatic dysfunction were excluded from the study. Patients who were not eligible for myeloablative SCT were considered for non-myeloablative SCT. Patients gave their written consent and were treated according to protocols approved by the institutional Ethics Committee.
The study was an observational cohort study. Preparative therapy was performed according to the primary disease and type of transplant. In general, patients with lymphoid malignancy were conditioned using a TBI (12 Gy)-containing regimen that included administration of cytarabine (8 g/m 2 ) and CY (120 mg/kg). Selective kidney shielding blocks were used during TBI and this reduced the renal dose to 10 Gy. 13 Conversely, patients with myeloid malignancy were conditioned using a non-TBI-containing regimen that included administration of BU (16 mg/kg) and CY (120 mg/kg). The plasma concentrations of BU were not monitored. TLI (7 Gy) was included in the BU/CY regimens in cases of mismatched or unrelated transplantation. Patients with severe aplastic anemia were also conditioned using a TLI-containing regimen. The preparative regimen for the non-myeloablative procedure consisted of CY (120 mg/kg) and fludarabine (125 mg/m 2 ). The GVHD prophylaxis regimen typically comprised a short course of MTX and CYA (CSP) or tacrolimus (FK). FK was used in cases involving either unrelated or mismatched transplantation. MTX was administered at 10 mg/m 2 i.v. on day þ 1 and at 7 mg/m 2 /day on days þ 3, þ 6 and þ 11. Continuous i.v. infusion of CSP and FK was started on day À1 at dosages of 3 mg/kg/day and 0.03 mg/kg/day, respectively. The target blood concentrations were 450-550 ng/ml for CSP and 10-20 ng/ml for FK, with the dosage of both drugs being adjusted according to renal function and the grade of acute GVHD. If no GVHD was present, both drugs were administered orally approximately 2 months after SCT, followed by tapering of the dosages between 3 and 6 months. Acute and chronic GVHD were diagnosed and graded according to previously established criteria. 14, 15 Tosulfloxacin and fluconazol were administered orally for 14 days before SCT. Trimethoprim-sulfamethoxazole (TMP 240 mg, SMX 1200 mg; 3 times per week) was also used to prevent pneumocystis pneumonia. CMV infection was monitored weekly by CMV antigenemia. Positive antigenemia, defined as 41 cell/65 000 cells, was treated using ganciclovir twice daily until negative CMV antigenemia was obtained.
Definition of post-SCT AKI AKI was defined and classified into three categories according to two current AKI definitions, the RIFLE and AKIN criteria and also by the conventional graded system introduced by Parikh et al., 11, 12 hereafter denoted as 'the Grading criteria'. A comparison of these AKI definitions is shown in Table 1 . AKI within the first 100 days after SCT was defined based on serum creatinine (Cr) and/or estimated glomerular filtration rate (eGFR) criteria proposed by each of the AKI definitions. The RIFLE criteria was determined on the basis of the most abnormal value of either Cr or eGFR criteria. Urine output criteria included in the RIFLE and AKIN definitions were not used, as we were unable to obtain accurate records of urine output from all the patients. The serum concentration of Cr was measured by an enzymatic method using an isotope-dilution mass spectrometry-traceable calibrator (N-assay L Creatinine Kit, Nittoubo Medical Co., Tokyo, Japan 
Statistical analysis
Data are shown as the mean±s.d. Comparisons between more than three groups were performed using analysis of variance for continuous variables and the w 2 -test for categorical variables. Patient follow-up was undertaken on 31 December 2007. All-cause mortality was determined at 1000 days following SCT. Cumulative survival curves were prepared by the Kaplan-Meier method and the log-rank test was used to analyze differences between the curves. Cox regression analysis was used to determine the association of each AKI category with mortality, followed by calculation of adjusted hazard ratio (HR) and 95% confidence intervals. The multivariate models incorporated a forward selection stepwise method using variables with a P-value of o0.20 in the univariate analyses. JMP version 7 (SAS Institute Japan, Cary, CA, USA) was used for all the statistical analyses. Values of Po0.05 were considered statistically significant.
Results

Demographics and baseline characteristics of patients following SCT
The baseline characteristics of the 141 m-allo patients, 60 nm-allo patients and 48 auto patients are summarized in Table 2 . The age of the patients at the time of SCT was AKI following SCT M Ando et al significantly higher in the auto group than in the other two SCT modalities. There was also a significant difference in age between the m-allo and the nm-allo groups. The auto transplant group had the lowest proportion of acute non-lymphocytic leukemia and the highest proportion of multiple myeloma and peripheral blood SCT compared with the other two modalities. There were no significant differences in gender proportion, baseline Cr level, ratio of related donors, frequency of acute and chronic GVHD and frequency of relapse between the three modalities.
Incidence of AKI classified according to the RIFLE, AKIN and grading criteria A comparison of the incidence data of post-SCT AKI according to the three different criteria is shown in Table 3 . The current incidence of any AKI ranged between 62 and 66% in m-allo, between 40 and 48% in nm-allo and between 10 and 19% in auto transplants. We found small differences in the number of patients classified as having AKI between the AKIN and the other two criteria. The AKIN criteria had the lowest ability to identify patients with AKI of the three criteria for all three SCT modalities, because of reduced sensitivity to identify the lowest category of AKI. Only two patients were classified into stage 1 of AKIN, based on a rapid increase in serum Cr X0.3 mg per 100 ml in the 48 h period after SCT. However, the ability to identify severe AKI (Xinjury or Xstage 2 or Xgrade 2) was identical between the three criteria (29% in m-allo, 17% in nm-allo and 2% in auto). The sensitivity of the RIFLE criteria was comparable with that of the grading criteria. Two patients in the m-allo group and three patients in the nm-allo group were classified into stage 3 of AKIN as they were receiving dialysis treatment.
Mortality of AKI classified according to the RIFLE, AKIN and grading criteria Mortality according to the three different criteria is shown in Table 4 . The mortality of patients with any AKI category was approximately 54% in m-allo, 48-50% in nmallo and 11-20% in auto transplants. Mortality increased in parallel with increases in AKI category, with mortality for Increase in serum Cr to X300% (X3-fold) from baseline or serum Cr X4.0 mg/dl (354 mmol/l) with an acute rise of at least 0.5 mg/ dl (44 mmol/l).
(C) Grading Grade 0 Decrease in GFR o25% of baseline Grade 1
Increase in serum Cro2-fold from baseline with a decrease in GFR 425% but o50% of baseline Grade 2 Increase in serum Cr X2-fold from baseline but not requiring dialysis Grade 3 Increase in serum Cr X2-fold from baseline and need for dialysis Abbreviations: GFR ¼ glomerular filtration rate; RIFLE ¼ risk, injury, failure, loss of kidney function, and end-stage kidney disease; AKIN ¼ acute kidney injury network; Cr ¼ creatinine; AKI ¼ acute kidney injury; ESKD ¼ end-stage kidney disease. a Post-SCT AKI is defined within the first 100 days after SCT.
Table 2
Demographics and baseline characteristics of the patients following SCT the highest category in the RIFLE and AKIN criteria increasing markedly in m-allo transplants and fatally in nm-allo transplants. The difference in mortality between AKI and no AKI according to the RIFLE criteria was marked and was especially apparent in the nm-allo group (48 versus 16%) compared with the m-allo group (54 versus 35%). This difference was not applicable to the auto group. Three patients in the m-allo group and three patients in the nm-allo group who required dialysis treatment died within 100 days of SCT. The Kaplan-Meier curves stratified by the RIFLE classification are shown in Figures (a), (b) and (c) and show clear differences in long-term survival between the various categories. The difference between curves 1000 days after SCT were significant for failure in m-allo transplants and for injury in nm-allo transplants, compared with no AKI (log-rank, Po0.0001). Similar curves of comparable significance were obtained when other criteria were used for stratification (data not shown).
Adjusted association of each AKI category with mortality and discriminative ability of each classification in allogeneic SCT Cox regression analysis, adjusted for age at SCT, baseline serum Cr, gender (male), absence or presence of acute GVHD Xgrade 2 and chronic GVHD, an unrelated donor and relapse of underlying diseases, showed that each category (Xinjury, Xstage 2 and Xgrade 2) independently predicted mortality in both of the m-allo and nm-allo groups (Table 5) . A large stepwise increment in hazard ratio for mortality was observed with increases in AKI category for all three classification systems. The discriminative ability for mortality was almost comparable in the three definitions. In the m-allo group, the AuROC curve was 0.649 (P ¼ 0.0005) with the RIFLE criteria, 0.643 (P ¼ 0.0007) with the AKIN criteria and 0.629 (P ¼ 0.0058) with the grading criteria. In the nm-allo group, the corresponding AuROC values were 0.766 (P ¼ 0.0006) with the RIFLE criteria, 0.734 (P ¼ 0.0008) with the AKIN criteria and 0.765 (P ¼ 0.0006) with the grading criteria ( Table 5) .
Discussion
The present study obtained the most recent data regarding the incidence and mortality of AKI following SCT, according to two new and one conventional AKI definition systems. Compared with the RIFLE and grading criteria, the AKIN criteria had the disadvantage of relatively poor sensitivity to identify the lowest category of AKI in any type of transplantation modality. All three criteria were found to have comparable utility for stratifying post-SCT patients with AKI according to mortality risk. Our study showed that the current incidence of post-SCT AKI was, at most, 66% in m-allo, 48% in nm-allo and 19% in auto transplants and that mortality was, at most, 54% in m-allo, 50% in nm-allo and 20% in auto transplants. The incidence rates for each of the allogeneic types were markedly higher than those of auto transplants, a finding that is comparable with those reported in previous studies.
1,2,5 The current incidence rates were considerably lower than those reported previously by Parikh et al. and Caliskan et al. using the grading criteria within the first 100 days after SCT (91-92% in m-allo, 90% in nm-allo and 52-57% in auto). 2, 11, 12, 17 In contrast, the present mortality rate was almost the same as previous estimations using the grading criteria (56-58% in m-allo transplants and 43% in nm-allo transplants, but no reference mortality in auto transplants alone). 2, 4, 11, 18 Most recently, Lopes et al. showed the incidence of AKI (40%) and 3-year mortality (48.8%) according to the AKIN criteria in m-allo, and the incidence (53.6%) and 5-year mortality (58.4%) in reduced intensity conditioning SCT according to the RIFLE criteria. 3, 19 Compared with our results, the incidences and mortality rates reported were lower in m-allo transplants and higher in RIC transplants. However, there were the following differences between the two studies: their cohort of m-allo transplants included 35.8% of myeloablative auto transplants and the length of the follow-up periods was longer than in our study. Unfortunately, this earlier study did not include a comparative assessment of their data with the grading criteria. Further epidemiological studies on post-SCT AKI according to the new AKI criteria are needed to estimate the recent incidence and mortality of AKI following SCT.
The Kaplan-Meier curves showed that the separation between the 'risk' and 'injury' curves in the m-allo group appeared to be obscure, compared with that seen in the nm-allo group. In addition, Cox regression analysis indicated that the HR of 'injury' for long-term mortality was significant but rather lower in the m-allo group (HR; 2.59) than in the nm-allo group (HR; 34.5). These differences suggest that the nm-allo group may be more vulnerable for exposure to the 'intermediate' level of AKI in the long term than the m-allo group. There was a significant difference in age at the time of SCT between the m-allo and nm-allo groups (38.3 versus 42.9 years). The older age of the nm-allo group may therefore have contributed to their higher risk of mortality after they were exposed to the 'intermediate' level of AKI.
The sensitivity of the AKIN criteria to identify patients with the lowest category of AKI was less than the other two criteria for all three transplant modalities. The AKIN criteria require at least two Cr values within a 48 h period rather than referring to a baseline Cr value in Stage 1.
A rapid, small increase (X0.3 mg per 100 ml) in serum Cr within 48 h could be under-recognized and often overlooked in the context of SCT. In fact, the 48 h time frame definition was not available in almost all post-SCT patients as we were not able to measure serum Cr frequently during the 100 days after SCT. This is most likely associated with the lower sensitivity of the AKIN criteria to identify stage-1 AKI, possibly leading to misclassification of AKI stages. In addition, Cox regression analysis showed that each of the categories higher than the intermediate stage were significant independent predictors of mortality in all three AKI definition systems. The AuROC curves for mortality showed equal significance for all the AKI definition systems. These results show that the RIFLE and AKIN classifications have almost the same predictive utility for mortality in patients with post-SCT AKI, but that they do not substantially improve the ability of the grading criteria to predict mortality in the context of SCT. Taken together, our results suggest that the RIFLE criteria are more favorable than the AKIN criteria as a uniform identification system for post-SCT AKI, and that clinical significance of previous epidemiological data according to the grading criteria remain valid today.
This study has some limitations. Firstly, we were not able to use urine output criteria in the new AKI criteria. When applying these new definitions to post-SCT AKI, it proved difficult to obtain accurate records of urine output in every patient throughout the SCT period. In addition, the volume status of patients during the acute period of SCT may have varied widely according to infusion therapy, whereas urinary tract obstruction sometimes occurred because of hemorrhagic cystitis induced by local adenoviral infections or as a side effect of administration of high dose of CY. These conditions may have resulted in a biased assessment of the true burden of post-SCT AKI using the two new criteria. The difficulties in practicing the urine output criteria are inherent in the assessment of the new AKI criteria especially in the setting of SCT. Secondly, we used serum Cr level and Cr-based estimates of GFR according to previous literature. 1,2 However, a challenge in the study of AKI in the post-SCT population is that serum Cr is a less effective measure of GFR in the setting of co-morbid illness. Cr-based estimates of GFR above 60 ml/min/1.73 m 2 are considered imprecise even in the general population. 16 Thirdly, although non-relapse mortality would add important information to this study, the current data set was not adequate to perform statistical analysis for nonrelapse mortality in all types of SCT in accordance with that described in previous studies. 2, 3 Finally, this was a single-center study on a relatively small cohort of SCT patients.
In summary, the variability in incidence of AKI following SCT most likely reflects the lack of a standard definition for post-SCT kidney disease, differences in the types of transplants investigated and variability in the length of the follow-up periods. It is, therefore, worthwhile to establish a uniform standard for diagnosing and classifying post-SCT AKI in comparative studies and carrying out robust epidemiological investigations internationally. The RIFLE criteria have shown promise as a uniform standard to identify and classify post-SCT patients with various degrees of AKI and to predict the mortality of these patients. However, this definition system does not substantially exceed the abilities of the conventional grading criteria. The incidence of AKI that we observed appears to be lower than that reported in previous studies, although the mortality of patients with higher categories of AKI still remains high in m-allo and nm-allo transplants. Emerging evidence suggests that even minor changes in serum Cr are associated with increased mortality. [7] [8] [9] [10] Despite the significant progress made in understanding the biology and mechanism of AKI in animal models, application of this knowledge into improved management and outcomes for patients has been limited. However, immediate fluid therapy for potential circulatory deficits, avoidance and minimizing the use of nephrotoxic agents and dosage adjustment of medication according to kidney function are sometimes effective for preventing worsening of the early stages of AKI. 20 Transplant physicians and nephrologists need to work together in the treatment of patients receiving SCT to identify early renal disease and also to examine small changes in serum creatinine concentration or promising new urinary biomarkers. 6, 21 Further efforts will be required to decrease the frequency of life-threatening AKI, with initial focus on m-allo and nmallo transplants.
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